InspireMD Inc (NSPR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
InspireMD Inc stock (NSPR) is currently trading at $1.77. InspireMD Inc PS ratio (Price-to-Sales) is 8.21. Analyst consensus price target for NSPR is $5.00. WallStSmart rates NSPR as Sell.
- NSPR PE ratio analysis and historical PE chart
- NSPR PS ratio (Price-to-Sales) history and trend
- NSPR intrinsic value — DCF, Graham Number, EPV models
- NSPR stock price prediction 2025 2026 2027 2028 2029 2030
- NSPR fair value vs current price
- NSPR insider transactions and insider buying
- Is NSPR undervalued or overvalued?
- InspireMD Inc financial analysis — revenue, earnings, cash flow
- NSPR Piotroski F-Score and Altman Z-Score
- NSPR analyst price target and Smart Rating
InspireMD Inc
📊 No data available
Try selecting a different time range
Smart Analysis
InspireMD Inc (NSPR) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
InspireMD Inc (NSPR) Key Strengths (2)
Revenue surging 61.60% year-over-year
Trading at 1.33x book value, attractively priced
Supporting Valuation Data
InspireMD Inc (NSPR) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 8.2x annual revenue
Micro-cap company with very limited liquidity and high volatility
Moderate institutional interest at 49.51%
Supporting Valuation Data
InspireMD Inc (NSPR) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.33) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 61.60%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (8.21) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -106.90%, Operating Margin at -383.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -106.90% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 61.60% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NSPR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NSPR's Price-to-Sales ratio of 8.21x trades at a deep discount to its historical average of 18.2x (20th percentile). The current valuation is 92% below its historical high of 102.65x set in Apr 2021, and 444% above its historical low of 1.51x in Sep 2016. Over the past 12 months, the PS ratio has compressed from ~16.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for InspireMD Inc (NSPR) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
InspireMD Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 9M with 62% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 62% YoY, reaching 9M. This pace significantly outperforms most MEDICAL DEVICES peers.
Spending 39% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can InspireMD Inc maintain 62%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact InspireMD Inc.
Bottom Line
InspireMD Inc is a high-conviction growth story with revenue accelerating at 62% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(22 last 3 months)
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -2,000 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -2,900 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -5,000 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -12,395 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -4,781 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -8,411 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -17,593 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -2,955 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -2,250 |
| Insider | Type | Shares |
|---|---|---|
GLEASON, SHANE THOMAS Chief Commercial Officer | Sell | -2,909 |
Data sourced from SEC Form 4 filings
Last updated: 8:26:27 AM
About InspireMD Inc(NSPR)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.